Development of Gene Therapies

Strategic, Scientific, Regulatory, and Access Considerations

Avery McIntosh, Oleksandr Sverdlov

• Publisher: Chapman and Hall/CRC
• Year: 2024
• ISBN:
  9781003855996
• Edition: 1
• Topic: Matemáticas
• Subtopic: Probabilidad y estadística

Cell and gene therapies have become the third major drug modality in pharmaceutical medicine of the 21st century after low molecular weight and antibody drugs. The gene therapy (GTx) field is rapidly advancing, and yet there are still fundamental scientific questions that remain to be answered. Development of GTx products poses unique challenges and opportunities for drug developers. However, there is lack of a systematic exposition of the GTx product development and the pivotal role of the biostatistician in this process. Development of Gene Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, statistical, and regulatory aspects of GTx development. Intended to provide an exposition to the GTx new product development through peer-reviewed papers written by subject matter experts in this emerging field, this book will be useful for researchers in gene therapy drug development, biostatisticians, regulators, patient advocates, graduate students, and the finance and business development community.

Key Features:

• A collection of papers covering a wide spectrum of topics in gene therapies (GTx), written by leading subject matter experts
• An exposition of the core principles of GTx product development, emerging business models, industry standards, best practices, and regulatory pathways
• An exposition of statistical and innovative modeling tools for design and analysis of clinical trials of GTx
• Insights into commercial models, access hurdles, and health economics of gene therapies
• Case studies of successful GTx approvals from core team members that developed the first two FDA-approved AAV gene therapies: Luxturna and Zolgensma
• A discussion of potential benefits and hurdles to be overcome for GTx in coming years from a multi-stakeholder perspective

Table of contents

• Cover Page
• Half-Title Page
• Series Page
• Title Page
• Copyright Page
• Dedication Page
• Contents
• Foreword
• List of Abbreviations
• Public Disclosure Statement
• Editors
• Contributors
• 1 Introduction: The Road to Gene Therapy
• 2 Driving AAV Drug Design to the Right Place, Right Amount, and Right Time
• 3 A Practical Guide to the Nonclinical Development of In Vivo Gene Therapies
• 4 Quantitative Systems Pharmacology Modeling of Adeno-Associated Virus Gene Therapies: Mechanistic Identification of Species-Translation Using Preclinical and Clinical Data
• 5 Bringing Gene Therapy to Patients: A Clinical Development Perspective Based on Brain and Neuromuscular Diseases
• 6 The Ethics of Gene Therapy
• 7 AAV Vector Immunogenicity in Gene Therapy: Mechanisms, Assessment, and Immunomodulation Strategies
• 8 Prenatal Somatic Cell Gene Therapy
• 9 Development of Gene Therapies for Ultra-Rare Disease
• 10 Statistical Innovation for Gene Therapy Development: Clinical Trial Design and Analysis Considerations
• 11 Biomarkers in Gene Therapy Development for Rare Diseases
• 12 Manufacturing, Analytical, and Process Comparability Challenges for Recombinant Adeno-Associated Virus (rAAV) Gene Therapy
• 13 Regulatory Considerations in the Development of Gene Therapy Products
• 14 Gene Therapy Clinical Safety Considerations: Short- and Long-Term
• 15 Development of Gene Therapies from an Academic Perspective
• 16 Commercial Models, Access Hurdles, and Health Economics of Gene Therapies
• 17 The Zolgensma Journey: A Groundbreaking Therapy for SMA
• 18 History and Development Story of Luxturna: Scientific and Regulatory Challenges
• 19 The Future of in vivo rAAV Gene Therapies for Rare Neurological Diseases
• Index